Month: March 2022

“Overall, African American men are 1.8 times more likely to be diagnosed with—and 2.2 times more likely to die from—prostate cancer than white men.” (From ZERO The End of Prostate Cancer) This point blank statement is the result of statistics that have remained fairly consistent over recent decades. This data has been the basis for keep reading

Once upon a fairly recent time, radical prostatectomy (RP) was the treatment of choice for prostate cancer (PCa), even for high risk disease. There were two main reasons for this: It was believed that PCa was a multifocal disease scattered throughout the gland, even if too small to be picked up by biopsy. Therefore, aggressively keep reading

We have occasionally posted blogs about the grassroots influence that prostate cancer (PCa) patients can have over trends in PCa treatment. For example, patient desire and demand for less invasive treatments that can diminish their quality of life played an enormous part in the evolution of focal therapies, such as our own Focal Laser Ablation. keep reading

When something could save lives, having an abundance of it on hand is a good thing. On the other hand, if there’s a scarcity of it, it won’t be readily available when it’s needed—and many lives will be put at risk. This is true for a prostate cancer (PCa) imaging agent called Gallium-68 (68Ga or keep reading

Everyone who wants to go through a prostate biopsy, raise your hand. What, no takers? Not surprising. Conventional transrectal ultrasound (TRUS) biopsies commonly involve 12-14 needles, and sometimes as many as 24 in a “saturation” biopsy. TRUS biopsies frequently involve pain and risk of infection. There can be side effects like bleeding and even erectile keep reading

The Radiological Society of North America (RSNA) was founded in 1915. It now has over 54,000 members. There are not only radiologists, but also other medical professionals and even medical physicists. At its annual gathering, its huge attendance makes it one of the largest medical conferences in the world... keep reading

Patients who choose robotic-assisted radical prostatectomy (RARP) believe it’s the best way to eradicate prostate cancer (PCa). In their mind, this equates to a cure. In fact, PCa can recur (come back) as long as 15 or more years after any whole-gland treatment. Increasingly, no one talks about “cure” anymore. Instead, “success” is defined as keep reading

Contrary to popular belief, a new study says you’re never too old to get high-risk prostate cancer (PCa). There’s been a recent trend to cut back on PSA screening for men over age 70. It wasn’t that long ago when such organizations as the American Urological Society and the American Society of Clinical Oncology promoted keep reading

Do you ever regret a decision that turns out to have a bad outcome? This is the situation for many prostate cancer (PCa) patients who chose radical prostatectomy (RP). A 2017 study found that 15% of PCa patients regret their treatment choice, with twice as many patients ruing the day they opted for RP or keep reading

I am frequently asked by patients how Focal Laser Ablation (FLA) compares to Radical Prostatectomy (RP) in terms of cancer control. After all, many of the men with localized prostate cancer (PCa) who come to Sperling Prostate Center have already been told by a urologist that they qualify for a nerve-sparing robotic RP that will keep reading